New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
dl-Methylphenidate (MPH) remains the most widely used pharmacological agent in the treatment of attention-deficit/hyperactivity disorder (ADHD). The predominantly dopaminergic mechanism of the psychostimulant actions has become more clearly defined. Neuroimaging and genetic studies are revealing the underlying neuropathology in ADHD. Novel extended-release (ER) MPH formulations now offer drug delivery options to overcome both the short-term actions of immediate-release (IR) MPH and the acute tolerance associated with the first-generation ER-MPH products. These novel MPH products apply proprietary technologies such as OROS (Alza), Diffucaps (Eurand) and SODAS (Elan) to offer both the convenience of once-a-day administration and absorption profiles resembling, to varying degrees, the standard multiple dose schedules of IR-MPH. The pharmacodynamics of the separate MPH enantiomers is in the process of further neuropharmacological characterisation. It is well established that dl-MPH undergoes marked stereoselective metabolism. Although l-MPH exhibits only minimal oral absorption, it may preferentially penetrate the brain, and interacts with ethanol to form the metabolite ethylphenidate. The newly approved resolved enantiomer product d-MPH is now available in an IR formulation, and when administered at one-half the dose to that of the racemate, is purported to produce a longer duration of clinical effect, despite essentially identical pharmacokinetics. A long-acting formulation of d-MPH, which employs the SODAS technology, is in the advanced stages of clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
Goldman, L. S. (1998) · JAMA · doi:10.1001/jama.279.14.1100 · Cited by 1,082 · cited 3×
“Pharmacotherapy remains the mainstay treatment for ADHD [2,5,7,33], although multimodal treatment approaches that integrate medication with psychotherapeutics, environmental, educational, and school-based interventions are generally advocated, especially with certain demographics [34].”
BackgroundResultCommittee on Quality Improvement, S. O. A.-D. D. (2000) · Pediatrics · doi:10.1542/peds.105.5.1158 · Cited by 1,076
Greenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
Wilens, T. E., Faraone, S. V., Biederman, J., & Gunawardene, S. (2003) · Pediatrics · doi:10.1542/peds.111.1.179 · Cited by 872
Biederman, J., Mick, E., Faraone, S. V., Braaten, E., Doyle, A., Spencer, T., Wilens, T. E., Frazier, E., & Johnson, M. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.36 · Cited by 863
Adult psychiatric status of hyperactive boys grown up
Mannuzza, S., Klein, R. G., Bessler, A., Malloy, P., & LaPadula, M. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.4.493 · Cited by 769
Clinical correlates of inpatient suicide
Busch, K. A., Fawcett, J., & Jacobs, D. G. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0105 · Cited by 750
Solanto, M. V. (1998) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)00175-7 · Cited by 677
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.11.1652 · Cited by 528
Wolraich, M. L., Greenhill, L. L., Pelham, W., Swanson, J., Wilens, T., Palumbo, D., Atkins, M., McBurnett, K., Bukstein, O., August, G., et al. (2001) · Pediatrics · doi:10.1542/peds.108.4.883 · Cited by 502
Pharmacotherapy of Attention-deficit/Hyperactivity Disorder Reduces Risk for Substance Use Disorder
Biederman, J., Wilens, T., Mick, E., Spencer, T., & Faraone, S. V. (1999) · Pediatrics · doi:10.1542/peds.104.2.e20 · Cited by 493
Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD
Volkow, N. D., & Swanson, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.11.1909 · Cited by 475 · cited 1×
“Controlled clinical studies of intranasal MPH have recently established dose–response relationships for both subjective and physiological effects [179].”
BackgroundVolkow, N. D., Wang, G., Fowler, J. S., Logan, J., Jayne, M., Franceschi, D., Wong, C., Gatley, S. J., Gifford, A. N., Ding, Y., et al. (2002) · Synapse · doi:10.1002/syn.10075 · Cited by 452 · cited 1×
“This action will amplify neurotransmission [49,50] by increasing synaptic cleft residence time of impulse-released dopamine [27,28].”
BackgroundPelham, W. E., Gnagy, E. M., Burrows-Maclean, L., Williams, A., Fabiano, G. A., Morrisey, S. M., Chronis, A. M., Forehand, G. L., Nguyen, C. A., Hoffman, M. T., et al. (2001) · Pediatrics · doi:10.1542/peds.107.6.e105 · Cited by 378
Mechanism of action of methylphenidate: Insights from PET imaging studies
Volkow, N. D., Fowler, J. S., Wang, G., Ding, Y., & Gatley, S. J. (2002) · Journal of Attention Disorders · doi:10.1177/070674370200601s05 · Cited by 353 · cited 1×
“The most widely prescribed medications to treat ADHD exhibit a prominent dopaminergic component of activity, as consistent with underlying dopaminergic dysfunction in ADHD [27-30].”
BackgroundVolkow, N. D., Wang, G., Fowler, J. S., Logan, J., Franceschi, D., Maynard, L., Ding, Y., Gatley, S. J., Gifford, A., Zhu, W., et al. (2002) · Synapse · doi:10.1002/syn.10038 · Cited by 321 · cited 6×
“This lack of enantiospecific analyses may be of little clinical relevance in view of the much lower concentrations of l-MPH in plasma and in dopaminergic regions of the human brain [28].”
BackgroundInfluentialInjuries to children with attention deficit hyperactivity disorder
DiScala, C., Lescohier, I., Barthel, M., & Li, G. (1998) · PEDIATRICS · doi:10.1542/peds.102.6.1415 · Cited by 305
KRATOCHVIL, C. J., HEILIGENSTEIN, J. H., DITTMANN, R., SPENCER, T. J., BIEDERMAN, J., WERNICKE, J., NEWCORN, J. H., CASAT, C., MILTON, D., & MICHELSON, D. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200207000-00008 · Cited by 292 · cited 3×
“In addition to the first-line ADHD treatments, other medication options include pemoline (Cylert®; Abbott Laboratories), whose use is limited by association with hepatoxicity [43]; the noradrenaline re-uptake inhibitor atomoxetine (Strattera®; Eli Lilly and Company) [44-46]; tricyclic antidepressants such as imipramin…”
BackgroundGREENHILL, L. L., HALPERIN, J. M., & ABIKOFF, H. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199905000-00011 · Cited by 268
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder
Biederman, J., Spencer, T., & Wilens, T. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003973 · Cited by 253 · cited 2×
“Pharmacotherapy remains the mainstay treatment for ADHD [2,5,7,33], although multimodal treatment approaches that integrate medication with psychotherapeutics, environmental, educational, and school-based interventions are generally advocated, especially with certain demographics [34].”
BackgroundMethodAnti-hyperactivity medication: methylphenidate and amphetamine
Seeman, P., & Madras, B. K. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000421 · Cited by 252
Swanson, J., Gupta, S., Lam, A., Shoulson, I., Lerner, M., Modi, N., Lindemulder, E., & Wigal, S. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.2.204 · Cited by 248
Swanson, J. M., Wigal, S. B., Wigal, T., Sonuga-Barke, E., Greenhill, L. L., Biederman, J., Kollins, S., Nguyen, A. S., DeCory, H. H., Hirshe Dirksen, S. J., et al. (2004) · Pediatrics · doi:10.1542/peds.113.3.e206 · Cited by 238
Swanson, J., Gupta, S., Guinta, D., Flynn, D., Agler, D., Lerner, M., Williams, L., Shoulson, I., & Wigal, S. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70038-x · Cited by 216 · cited 1×
“1 OROS® technology (Concerta®) Seeking to avoid the aforementioned acute tolerance perhaps associated with first-generation ER-MPH formulations [79,167,168], the OROS® (osmotic, ER oral delivery system) MPH product was developed by Alza.”
Swanson, J., Kinsbourne, M., Roberts, W., & Zucker, K. (1978) · PEDIATRICS · doi:10.1542/peds.61.1.21 · Cited by 205 · cited 1×
“Based on time–response analysis [165], the first 2 – 3 h after IR-MPH administration corresponds to the greatest improvement in cognitive performance.”
BackgroundMilberger, S., Biederman, J., Faraone, S. V., Guite, J., & Tsuang, M. T. (1997) · Biological Psychiatry · doi:10.1016/0006-3223(95)00653-2 · Cited by 200
Swanson, J. M., & Volkow, N. D. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00433-8 · Cited by 173 · cited 1×
“In studies utilising different oral formulations, the AUCinf value for the l-isomer has been reported to reach only 1 – 15% that of d-MPH [71,94,98] (Table 2).”
BackgroundPelham, W. E., Sturges, J., Hoza, J., Schmidt, C., Bijlsma, J. J., Milich, R., & Moorer, S. (1987) · PEDIATRICS · doi:10.1542/peds.80.4.491 · Cited by 167 · cited 3×
“Both have been reported to produce comparable beneficial effects in the treatment of ADHD [159-161], although a few specific behavioural differences have been noted [159].”
BackgroundResultEffects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD
Arnold, L. E., Elliott, M., Sachs, L., Bird, H., Kraemer, H. C., Wells, K. C., Abikoff, H. B., Comarda, A., Conners, C. K., Elliott, G. R., et al. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.4.713 · Cited by 159 · cited 1×
“Pharmacotherapy remains the mainstay treatment for ADHD [2,5,7,33], although multimodal treatment approaches that integrate medication with psychotherapeutics, environmental, educational, and school-based interventions are generally advocated, especially with certain demographics [34].”
BackgroundMethylphenidate Dosing: Twice Daily Versus Three Times Daily
Stein, M. A., Blondis, T. A., Schnitzler, E. R., O'Brien, T., Fishkin, J., Blackwell, B., Szumowski, E., & Roizen, N. J. (1996) · Pediatrics · doi:10.1542/peds.98.4.748 · Cited by 151 · cited 1×
“00 h) has been reported not to affect sleeping patterns [162], but may significantly diminish appetite [163].”
BackgroundCox, D. J., Merkel, R. L., Penberthy, J. K., Kovatchev, B., & Hankin, C. S. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200403000-00007 · Cited by 120
Faraone, S. V., Biederman, J., & Roe, C. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200210000-00005 · Cited by 91
Newcorn, J. H., Schulz, K., Harrison, M., DeBellis, M. D., Udarbe, J. K., & Halperin, J. M. (1998) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70064-x · Cited by 68
Cited by
Evolution of the treatment of attention-deficit/hyperactivity disorder in children: A review
Findling, R. L. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.006 · Cited by 129
A Comprehensive In Vitro Screening of d-, l- , and dl-threo -Methylphenidate: An Exploratory Study
Markowitz, J. S., DeVane, C. L., Pestreich, L. K., Patrick, K. S., & Muniz, R. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.687 · Cited by 109
“The presystemic metabolism and metabolic clearance of dl-MPH is an enantioselective process resulting in markedly higher plasma concentrations of d -MPH relative to l-MPH ( Markowitz et al. 2003; Patrick et al. 2005).”
Self-citationThe psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT1A receptor
Markowitz, J. S., Markowitz, J. S., DeVane, C. L., Ramamoorthy, S., Zhu, H.-J., & Zhu, H.-J. (2009) · Die Pharmazie · doi:10.31083/ph.2009.8691 · Cited by 68
Self-citationSchachar, R., Ickowicz, A., Crosbie, J., Donnelly, G. A. E., Reiz, J. L., Miceli, P. C., Harsanyi, Z., & Darke, A. C. (2008) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0039 · Cited by 43
Castells, X., Cunill, R., & Capellà, D. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1390-7 · Cited by 41
Metadata
- Authors
- Patrick, K. S., González, M. A., Straughn, A. B., & Markowitz, J. S.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2005-01
- Volume
- 2
- Issue
- 1
- Pages
- 121-143
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2167718351
- Cited by
- 57
- References
- 34
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.